Preclinical Evaluation of a New Series of Albumin-Binding <sup>177</sup>Lu-Labeled PSMA-Based Low-Molecular-Weight Radiotherapeutics
Prostate-specific membrane antigen (PSMA)-based low-molecular-weight agents using beta(β)-particle-emitting radiopharmaceuticals is a new treatment paradigm for patients with metastatic castration-resistant prostate cancer. Although results have been encouraging, there is a need to improve the tumor...
Збережено в:
| Автори: | , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
MDPI AG
2023-08-01
|
| Серія: | Molecules |
| Предмети: | |
| Онлайн доступ: | https://www.mdpi.com/1420-3049/28/16/6158 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|